Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | TNF | P01375 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | RECQL | P46063 | 1/20 | 1.00 |
| ▸ | IL2 | P60568 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.85 |
| ▸ | SLCO2B1 | O94956 | 2/20 | 0.85 |
| ▸ | KDM1A | O60341 | 3/20 | 0.81 |
| ▸ | XDH | P47989 | 3/20 | 0.78 |
| ▸ | KDM4A | O75164 | 1/20 | 0.75 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.75 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.73 |
| ▸ | POLB | P06746 | 3/20 | 0.63 |
| ▸ | GAA | P10253 | 3/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Galuteolin SCHEMBL30282117 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDM4ETDP1L3MBTL1 | |
| Galuteolin SCHEMBL19523005 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDM4ETDP1L3MBTL1 | |
| Galuteolin SCHEMBL149119 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDM4ETDP1L3MBTL1 | |
| Galuteolin SCHEMBL2126750 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDM4ETDP1L3MBTL1 | |
| Galuteolin SCHEMBL16755609 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDM4ETDP1L3MBTL1 | |
| Galuteolin SCHEMBL17232556 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDM4ETDP1L3MBTL1 | |
| Galuteolin SCHEMBL149118 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDM4ETDP1L3MBTL1 | |
| Galuteolin SCHEMBL4984197 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDM4ETDP1L3MBTL1 | |
| Galuteolin SCHEMBL22510086 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDM4ETDP1L3MBTL1 | |
| Galuteolin SCHEMBL29374275 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDM4ETDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1541 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122080093-A | Compounds effective in treating liver toxicity and fatty liver disease and uses thereof | — | 2026-05-26 | — | — | CN | claimed |
| CN-122042866-A | Method for separating, detecting and identifying flavonoid component in cocoa | 中国热带农业科学院香料饮料研究所 | 2026-05-15 | — | — | CN | claimed |
| WO-2026087503-A1 | NON-THERAPEUTIC USE OF ARONIA EXTRACT FOR ENHANCING EXECUTIVE FUNCTION | BIOACTOR BV (NL) | 2026-04-30 | — | — | WO | claimed |
| EP-4626258-A1 | NON-THERAPEUTIC USE OF AN ARONIA BERRY EXTRACT | BioActor B.V. (NL) | 2025-10-08 | — | — | EP | claimed |
| EP-4609911-A2 | COMPOUNDS EFFECTIVE IN TREATING HEPATOTOXICITY AND FATTY LIVER DISEASES AND USES THEREOF | Sinew Pharma Inc. (TW) | 2025-09-03 | — | — | EP | claimed |
| US-12383573-B2 | Use of luteolin-7-O-glucoside or luteolin-7-O-glucuronide in preparation of medicine for eye injuries | Beijing Chengyi Investment Co., Ltd. (CN) | 2025-08-12 | — | — | US | claimed |
| US-20250228794-A1 | HOMOVANILLYL ALCOHOL (HVA), HVA ISOMER, METHODS OF MAKING COMPOSITIONS COMPRISING SUCH COMPOUNDS, AND METHODS USING SUCH COMPOUNDS | NESTLE SA (CH) | 2025-07-17 | — | — | US | claimed |
| CN-119792369-A | Chrysanthemum extract, preparation method and application | 南京怡然生物科技有限公司 | 2025-04-11 | — | — | CN | claimed |
| CN-119700875-A | Oil tea cake extract and preparation method and application thereof | 湖南科技大学 | 2025-03-28 | — | — | CN | claimed |
| CN-119524140-A | Compositions and methods for preventing or treating adipose pancreas, ameliorating pancreatic lesions, diabetes, or other related conditions caused by adipose pancreas | 雅各生技有限公司 | 2025-02-28 | — | — | CN | claimed |
| JP-2003504327-A | — | — | 2003-02-04 | — | — | JP | claimed |
| US-20020165207-A1 | Compositions and methods for the treatment of diabetic neuropathy | QUIGLEY CORPORATION, THE | 2002-11-07 | — | — | US | claimed |
| US-20020115618-A1 | Method and composition for the topical treatment of diabetic neuropathy | QUIGLEY CORPORATION, THE | 2002-08-22 | — | — | US | claimed |
| EP-1223928-A2 | USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS | Prendergast, Patrick Thomas (IE) | 2002-07-24 | — | — | EP | claimed |
| WO-2002049575-A2 | METHOD AND COMPOSITION FOR THE TREATMENT OF DIABETIC NEUROPATHY | THE QUIGLEY CORPORATION (US) | 2002-06-27 | — | — | WO | claimed |
| WO-2001003681-A2 | USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS | PRENDERGAST PATRICK T (IE) | 2001-01-18 | — | — | WO | claimed |
| US-6054128-A | COMPRISING VITAMIN B6, VITAMIN B12 AND FOLIC ACID FOR REDUCING THE SERUM HOMOCYSTEINE LEVEL, ANTIOXIDANTS TO REDUCE OXIDATION OF LOW DENSITY LIPOPROTEINS; SELENIUM TO REDUCE PLATELET AGGREGATION AND MODULATE PROSTAGLANDIN SYNTHESIS | WAKAT DIANE (US) | 2000-04-25 | — | — | US | claimed |
| EP-0980203-A1 | ANTIMICROBIAL PREVENTION AND TREATMENT OF HUMAN IMMUNEDEFICIENCY VIRUS AND OTHER INFECTIOUS DISEASES | Squires, Meryl (US) | 2000-02-23 | — | — | EP | claimed |
| WO-1998042188-A1 | ANTIMICROBIAL PREVENTION AND TREATMENT OF HUMAN IMMUNEDEFICIENCY VIRUS AND OTHER INFECTIOUS DISEASES | SQUIRES MERYL (US) | 1998-10-01 | — | — | WO | claimed |
| EP-0317453-B1 | MEDICINAL COMPOSITIONS BASED ON FLAVONOIDS AND SAPONINS EXTRACTED FROM CHRYSANTHELLUM, PROCESS FOR THEIR MANUFACTURE AND THERAPEUTICAL USES | IPHYM SA Société Anonyme dite : (FR) | 1993-02-03 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12383573-B2 | Use of luteolin-7-O-glucoside or luteolin-7-O-glucuronide in preparation of medicine for eye injuries | UGT1A7, UGT2B7, LGALS7; LGALS7B | MEN1 1812/4885KMT2A 4352/4885KDM4E 2810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.